521 related articles for article (PubMed ID: 15616327)
21. Standardization of an experimental murine model of invasive pulmonary aspergillosis.
Sheppard DC; Graybill JR; Najvar LK; Chiang LY; Doedt T; Kirkpatrick WR; Bocanegra R; Vallor AC; Patterson TF; Filler SG
Antimicrob Agents Chemother; 2006 Oct; 50(10):3501-3. PubMed ID: 17005844
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis.
Gavaldà J; Martín T; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Puigfel Y; Ruiz I; Pahissa A
Clin Microbiol Infect; 2005 Dec; 11(12):999-1004. PubMed ID: 16307554
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model.
Chandrasekar PH; Cutright J; Manavathu E
J Antimicrob Chemother; 2000 May; 45(5):673-6. PubMed ID: 10797091
[TBL] [Abstract][Full Text] [Related]
24. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma.
Chen J; Li H; Li R; Bu D; Wan Z
J Antimicrob Chemother; 2005 Jan; 55(1):31-7. PubMed ID: 15563516
[TBL] [Abstract][Full Text] [Related]
25. Disseminated invasive aspergillosis in an apparently immunocompetent host.
Raja NS; Singh NN
J Microbiol Immunol Infect; 2006 Feb; 39(1):73-7. PubMed ID: 16440127
[TBL] [Abstract][Full Text] [Related]
26. Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis.
Moosa MY; Alangaden GJ; Manavathu E; Chandrasekar PH
J Antimicrob Chemother; 2002 Jan; 49(1):209-13. PubMed ID: 11751792
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.
Verweij PE; Oakley KL; Morrissey J; Morrissey G; Denning DW
Antimicrob Agents Chemother; 1998 Apr; 42(4):873-8. PubMed ID: 9559799
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model.
Nagasaki Y; Eriguchi Y; Uchida Y; Miyake N; Maehara Y; Kadowaki M; Harada M; Akashi K; Shimono N
J Antimicrob Chemother; 2009 Aug; 64(2):379-82. PubMed ID: 19465436
[TBL] [Abstract][Full Text] [Related]
29. [A pharmacodynamics study of an intravitreal amphotericin B drug delivery system for the treatment of experimental Aspergillus fumigatus endophthalmitis].
Yang X; Dong XG; Liu AM; Sun SY; Xie LX; Wang SG
Zhonghua Yan Ke Za Zhi; 2007 Jun; 43(6):546-53. PubMed ID: 17897534
[TBL] [Abstract][Full Text] [Related]
30. Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis.
Falk R; Grunwald J; Hoffman A; Domb AJ; Polacheck I
Antimicrob Agents Chemother; 2004 Sep; 48(9):3606-9. PubMed ID: 15328139
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis.
Gavaldà J; Martín MT; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Puigfel Y; Ruíz I; Pahissa A
Antimicrob Agents Chemother; 2005 Jul; 49(7):3028-30. PubMed ID: 15980392
[TBL] [Abstract][Full Text] [Related]
32. Vitamin D and experimental invasive aspergillosis.
Sirivoranankul C; Martinez M; Chen V; Clemons KV; Stevens DA
Med Mycol; 2014 Nov; 52(8):847-52. PubMed ID: 25231772
[TBL] [Abstract][Full Text] [Related]
33. Multidrug resistance in Aspergillus fumigatus.
Warris A; Weemaes CM; Verweij PE
N Engl J Med; 2002 Dec; 347(26):2173-4. PubMed ID: 12501236
[No Abstract] [Full Text] [Related]
34. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B.
Singh J; Rimek D; Kappe R
Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441
[TBL] [Abstract][Full Text] [Related]
35. Tolerance to amphotericin B in clinical isolates of Candida tropicalis.
Barchiesi F; Maracci M; Baldassarri I; Spreghini E; Giannini D; Scalise G
Diagn Microbiol Infect Dis; 2004 Nov; 50(3):179-85. PubMed ID: 15541603
[TBL] [Abstract][Full Text] [Related]
36. [Severe aspergillus pneumonia (necrotizing lung aspergillosis)].
Noll WL; van Garsse LG; Stam J
Ned Tijdschr Geneeskd; 1972 Apr; 116(17):685-90. PubMed ID: 4553265
[No Abstract] [Full Text] [Related]
37. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis.
Allendoerfer R; Loebenberg D; Rinaldi MG; Graybill JR
Antimicrob Agents Chemother; 1995 Jun; 39(6):1345-8. PubMed ID: 7574528
[TBL] [Abstract][Full Text] [Related]
39. Antifungal activity of Leptospermum petersonii oil volatiles against Aspergillus spp. in vitro and in vivo.
Hood JR; Burton D; Wilkinson JM; Cavanagh HM
J Antimicrob Chemother; 2010 Feb; 65(2):285-8. PubMed ID: 19952013
[TBL] [Abstract][Full Text] [Related]
40. Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis.
Ruijgrok EJ; Fens MH; Bakker-Woudenberg IA; van Etten EW; Vulto AG
Antimicrob Agents Chemother; 2006 May; 50(5):1852-4. PubMed ID: 16641459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
